UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Has $67.61 Million Stock Holdings in Phreesia, Inc. $PHR

Key Points

• UBS Asset Management increased its holdings in Phreesia, Inc. by 108.7% in the first quarter, owning approximately 4.45% of the company with a value of $67.6 million.
• Phreesia's stock opened at $24.20 and has seen a 14.9% revenue increase year-over-year, despite recent insider sales contributing to a negative return on equity.
• Research analysts have a consensus rating of "Buy" for Phreesia, with price targets ranging from $33.00 to $36.00, suggesting potential growth for the company.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Phreesia, Inc. (NYSE:PHR - Free Report) by 108.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,644,988 shares of the company's stock after buying an additional 1,377,904 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned about 4.45% of Phreesia worth $67,606,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. increased its position in Phreesia by 2.4% during the first quarter. Vanguard Group Inc. now owns 4,936,515 shares of the company's stock worth $126,177,000 after buying an additional 113,405 shares during the last quarter. Greenhouse Funds LLLP increased its position in Phreesia by 2.9% during the first quarter. Greenhouse Funds LLLP now owns 2,956,910 shares of the company's stock worth $75,579,000 after buying an additional 83,018 shares during the last quarter. Champlain Investment Partners LLC increased its position in Phreesia by 20.0% during the first quarter. Champlain Investment Partners LLC now owns 2,946,489 shares of the company's stock worth $75,312,000 after buying an additional 490,340 shares during the last quarter. American Century Companies Inc. increased its position in Phreesia by 3,741.9% during the first quarter. American Century Companies Inc. now owns 983,440 shares of the company's stock worth $25,137,000 after buying an additional 957,842 shares during the last quarter. Finally, Park West Asset Management LLC increased its position in Phreesia by 111.2% during the first quarter. Park West Asset Management LLC now owns 894,501 shares of the company's stock worth $22,863,000 after buying an additional 470,931 shares during the last quarter. 92.10% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Phreesia

In related news, General Counsel Allison C. Hoffman sold 3,133 shares of the stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $23.28, for a total value of $72,936.24. Following the completion of the transaction, the general counsel owned 139,037 shares of the company's stock, valued at $3,236,781.36. This represents a 2.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Evan Roberts sold 45,147 shares of the stock in a transaction dated Wednesday, August 27th. The stock was sold at an average price of $32.02, for a total transaction of $1,445,606.94. Following the completion of the transaction, the insider directly owned 727,768 shares of the company's stock, valued at $23,303,131.36. This trade represents a 5.84% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 128,250 shares of company stock valued at $3,737,117. Corporate insiders own 5.50% of the company's stock.

Phreesia Stock Performance

Shares of NYSE PHR traded up $1.00 during mid-day trading on Thursday, hitting $24.28. The company had a trading volume of 801,987 shares, compared to its average volume of 1,182,744. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.12 and a quick ratio of 2.12. The business's 50-day simple moving average is $27.62 and its 200-day simple moving average is $26.39. Phreesia, Inc. has a 12 month low of $17.07 and a 12 month high of $32.76. The firm has a market cap of $1.45 billion, a P/E ratio of -57.81 and a beta of 0.72.

Phreesia (NYSE:PHR - Get Free Report) last released its earnings results on Thursday, September 4th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.08. Phreesia had a negative net margin of 5.35% and a negative return on equity of 8.75%. The business had revenue of $117.26 million during the quarter, compared to analysts' expectations of $116.39 million. During the same quarter last year, the company earned ($0.03) earnings per share. The firm's revenue was up 14.9% on a year-over-year basis. Phreesia has set its FY 2026 guidance at EPS. As a group, analysts predict that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PHR has been the subject of a number of recent analyst reports. Canaccord Genuity Group upped their price target on shares of Phreesia from $34.00 to $38.00 and gave the company a "buy" rating in a report on Friday, September 5th. Citigroup restated an "outperform" rating on shares of Phreesia in a report on Monday, September 8th. Piper Sandler upped their price target on shares of Phreesia from $33.00 to $34.00 and gave the company an "overweight" rating in a report on Friday, September 5th. DA Davidson upgraded shares of Phreesia to a "strong-buy" rating in a report on Monday, September 8th. Finally, Mizuho initiated coverage on shares of Phreesia in a report on Wednesday, August 27th. They set an "outperform" rating and a $36.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating and twelve have given a Buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $34.08.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.